A Year In Review
The ADC space is expanding faster than ever, with a 33% surge in new drugs and 23% in new clinical trials. Breakthroughs in bispecific ADCs and dual-payload technologies are shaping the future, while $64.3 billion in deals signal strong industry confidence.
Our Landscape Review delivers the key insights you need to stay competitive—from clinical trends to investment opportunities. Download now to make smarter, strategic decisions in this rapidly evolving field.
Download Now
Lead the future of ADC innovation!
The Beacon ADC 2024 Landscape Review is your definitive guide to the latest advancements in antibody-drug conjugates. Explore novel payloads, targets, and key clinical and commercial trends.
Report Contents
The Drug Landscape
A deep dive into the ADC assets added to Beacon in 2024, highlighting growth trends, emerging modalities, and key therapeutic targets.
The Trial Landscape
Analysis of the 660 new ADC trials, including phase distribution, success rates, and trial discontinuation insights.
The Commercial Market
A review of the 99 ADC deals in 2024, analyzing investment trends, partnerships, and market shifts.
The Future of ADCs
Emerging trends in ADC drug development, from novel payload mechanisms to expanding clinical applications.
Regulatory Announcements
Key ADC approvals and regulatory developments shaping the industry’s evolving compliance landscape.
Previous ADC Landscape Reviews
ADC 2024 H1 Landscape Review
An analysis of the ADC landscape in H1 of 2024
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
